Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

HER2+ Gastric Cancer

November 4th 2016

Ongoing Research in Gastric Cancer; Antiangiogenic Therapy Upfront and Immunotherapy

November 4th 2016

Treatment for Recurrent Gastroesophageal Cancer

November 4th 2016

Palliative Management for Patients with Gastroesophageal Cancers

November 4th 2016

Maintenance Therapy for Gastroesophageal Cancer

November 4th 2016

HER2-Positive Gastric Cancer

November 4th 2016

Up-front Treatment of Metastatic Gastroesophageal Cancer

November 4th 2016

Should Anthracyclines Be Given in Advanced Gastroesophageal Cancer?

November 4th 2016

Multidisciplinary Management of Locally Advanced Gastroesophageal Cancer

November 4th 2016

Molecular Testing to Determine Gastric Cancer Treatment

November 4th 2016

Genomic Analysis in Gastric Cancer

November 4th 2016

Classification of Gastric and Gastroesophageal Junction Cancers

November 4th 2016

Targeting CD47 May Open "Exciting" Door to Novel Combos

November 3rd 2016

Gregory L. Beatty, MD, PhD, who focuses his research on understanding the role of innate immunity in gastrointestinal malignancies, discusses CD47 as an anticancer target.

The Future of HCC Management

October 31st 2016

Emerging Therapies in Advanced HCC

October 31st 2016

Clinical Experience with Regorafenib in HCC

October 31st 2016

Impact of RESORCE Findings on HCC Clinical Practice

October 31st 2016

Understanding the RESORCE Data in Second-Line HCC

October 31st 2016

Second-Line HCC: A Historical Perspective

October 31st 2016

HCC: Considerations in First-Line Use of Sorafenib

October 31st 2016